Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of “Hold” from Analysts

Sage Therapeutics, Inc. (NASDAQ:SAGE) has been given an average rating of “Hold” by the twenty-one research firms that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, seventeen have issued a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $12.83.

Several analysts recently weighed in on SAGE shares. Wedbush reduced their price objective on Sage Therapeutics from $9.00 to $8.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 9th. Scotiabank reduced their price objective on Sage Therapeutics from $17.00 to $14.00 and set a “sector outperform” rating on the stock in a research note on Wednesday, October 30th. Bank of America dropped their target price on Sage Therapeutics from $11.00 to $6.00 and set an “underperform” rating for the company in a research report on Wednesday, October 9th. Oppenheimer dropped their target price on Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. dropped their target price on Sage Therapeutics from $12.00 to $10.00 and set a “neutral” rating for the company in a research report on Tuesday, August 6th.

Sage Therapeutics Stock Up 6.6 %

NASDAQ:SAGE opened at $5.17 on Friday. The stock’s 50-day simple moving average is $6.75 and its 200 day simple moving average is $9.10. The firm has a market capitalization of $316.26 million, a PE ratio of -0.93 and a beta of 0.92. Sage Therapeutics has a twelve month low of $4.62 and a twelve month high of $28.26.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share for the quarter, missing the consensus estimate of ($1.52) by ($0.01). The business had revenue of $11.87 million during the quarter, compared to analyst estimates of $10.80 million. Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. The business’s quarterly revenue was up 337.1% compared to the same quarter last year. During the same period last year, the business earned ($2.81) earnings per share. On average, analysts anticipate that Sage Therapeutics will post -6.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Sage Therapeutics

A number of hedge funds have recently added to or reduced their stakes in SAGE. ProShare Advisors LLC increased its holdings in Sage Therapeutics by 9.0% in the first quarter. ProShare Advisors LLC now owns 13,713 shares of the biopharmaceutical company’s stock worth $257,000 after purchasing an additional 1,130 shares in the last quarter. State Board of Administration of Florida Retirement System increased its holdings in Sage Therapeutics by 9.8% in the first quarter. State Board of Administration of Florida Retirement System now owns 16,644 shares of the biopharmaceutical company’s stock worth $312,000 after purchasing an additional 1,480 shares in the last quarter. Vanguard Group Inc. increased its holdings in Sage Therapeutics by 8.1% in the first quarter. Vanguard Group Inc. now owns 5,751,373 shares of the biopharmaceutical company’s stock worth $107,781,000 after purchasing an additional 432,013 shares in the last quarter. Lazard Asset Management LLC bought a new stake in Sage Therapeutics in the first quarter worth approximately $127,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in Sage Therapeutics by 69.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 811,934 shares of the biopharmaceutical company’s stock worth $15,217,000 after purchasing an additional 333,805 shares in the last quarter. 99.22% of the stock is currently owned by institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.